Dr. Rinath Jeselsohn reviewed estrogen receptor biology in ER-positive breast cancer, highlighting chromatin regulation, co-regulators, and genetic alterations driving endocrine resistance and informing novel ER-targeted therapies.

Dr. Virginia Borges reviewed endocrine resistance in HR-positive breast cancer, highlighting ESR1 alterations, PI3K/AKT/mTOR signaling, ER loss, and host factors that support personalized treatment strategies.

Dr. Erica Mayer reviewed emerging oral SERDs, highlighting improved progression-free survival, combination strategies, and differing toxicity profiles. Ongoing trials will define optimal use across treatment settings.

Dr. Kay Yeung reviewed novel therapies targeting endocrine resistance, including CDK2, KAT6, and CDK7 inhibitors. Early results support biomarker-driven strategies to overcome resistance in ER-positive breast cancer.

Dr. Nan Chen reviewed estrogen-androgen signaling in ER-positive breast cancer. AR-targeted therapies showed limited overall benefit, though selected AR-high tumors may respond, supporting biomarker-guided treatment.

Panelists discussed oral SERDs and combination therapies for metastatic ER-positive breast cancer, emphasizing biomarker-guided treatment, resistance mechanisms, and balancing efficacy with toxicity.